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Interleukin-17 (IL-17) is a T-cell-derived cytokine that
promotes inflammatory pathology in autoimmune
diseases. Blocking IL-17A interactions with its en-
dogenous IL-17 receptor (IL-17RA) can constitute
an important target for therapeutic intervention.
Here, we utilized a directed evolution approach to
generate soluble IL-17RA mutants that exhibit
increased IL-17A binding affinity and thermostability,
relative to the wild-type. Human fibroblast cell-based
assay and in vivo analysis in mice indicated that two
improved IL-17RA mutants efficiently inhibit the
secretion of IL-17A-induced proinflammatory cyto-
kines. Analysis of one of these mutants in a psoriasis
mouse model showed its efficacy in promoting the
recovery of psoriasis plaques. This mutant can be
used as a promising drug candidate for the treatment
of psoriasis and may be a therapeutic agent for
various other autoimmune diseases.
INTRODUCTION
Interleukin 17 (IL-17) represents a family of proinflammatory
cytokines consisting of six members, termed IL-17A–F. IL-17A
is expressed by a unique lineage of CD4 T cells (Th-17) and is
known to stimulate fibroblasts, endothelial cells, epithelial cells,
and macrophages to produce multiple proinflammatory media-
tors, including IL-1, IL-6, tumor necrosis factor (TNF)-a, NOS-
2, and chemokines, resulting in the induction of inflammation
(Aggarwal et al., 2003; Onishi and Gaffen, 2010). Previous
studies have shown that IL-17 is actively involved in a range of
pathologic conditions in humans, ranging from common asthma
to several autoimmune diseases, such as rheumatoid arthritis
(RA), psoriasis, and inflammatory bowel disease, as well as
allergen-specific immune responses (Iwakura and Ishigame,
2006; Kolls and Linde´n, 2004; Nakae et al., 2002). The signaling
of IL-17 in several cell types is mediated by binding to endoge-202 Chemistry & Biology 20, 202–211, February 21, 2013 ª2013 Elsenous IL-17 receptors (IL-17R), a group comprising five receptor
types, termed IL-17RA–IL-17RE (Aggarwal and Gurney, 2002).
Recently, it was shown that IL-17A signaling ismediated by a het-
eromeric complex containing IL-17RA and IL-17RC chains (Toy
et al., 2006). Both receptors are single 90 kDa transmembrane
proteins and contain conserved structural motifs (Gaffen, 2009;
Kramer et al., 2007). The IL-17 receptors are not homologs to
any known receptors and possess unique signaling properties,
which enable Th-17 cells to act as a bridge between cells of
the innate and adaptive immune systems (Ely et al., 2009).
The roles of the IL-17A pathway in mediating inflammation and
autoimmune disorders render it an attractive target for interven-
tion. Blocking of IL-17A binding to its receptor may lead to the
abolishment of downstream signaling effects and thus prevent
various inflammatory disorders. A direct approach for targeting
the IL-17A pathway would involve the use of antibodies or
soluble IL-17RA that will bind IL-17A with high affinity, and
thus prevent ligand binding to the endogenous receptor. In
general, antibody-based therapeutics provide the advantage of
a stable scaffold with high affinity and specificity to the target
ligand. However, antibodies can bind the target ligand at sites
that are remote or only partially overlap with the receptor binding
site and thus compromise the ability of the antibody to prevent
the endogenous ligand-receptor interaction. For example, the
recognition of IL-17A by the antibody CAT-2200 only partially
overlaps with the binding site of the IL-17RA for IL-17 (Gerhardt
et al., 2009) (Figure S1 available online). In contrast, soluble
receptors can effectively compete with the endogenous cell
surface receptors for the native ligand binding site and provide
a variety of scaffolds with different size, stability, and affinity.
In the past few years, directed evolution methodologies have
proven to be highly valuable for generating proteins with im-
proved functions. Directed evolution methodologies are based
on the principles of natural Darwinian evolution and consist of
two major steps: (i) creation of genetic diversity in the target
gene in the form of gene libraries, and (ii) effective selection or
screening of those libraries for the desired activity (Aharoni
et al., 2005; Tao and Cornish, 2002). Directed evolution has
been employed for improving the catalytic activity of enzymes,
for altering substrate specificity, for enhancing thermostability,
and for augmenting expression in recombinant systems. Invier Ltd All rights reserved
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significantly enhanced affinity for various ligands (Gai and
Wittrup, 2007; Umetsu et al., 2010).
In this work, we utilized directed evolution methodologies to
generate IL-17RA extracellular domain (ECD) (Gaffen, 2009)
variants that show high affinity for IL-17A, potent inhibition of
IL-17-induced cytokine secretion from cells, and the inhibition
of psoriasis plaque formation in a mouse model. We first gener-
ated a focused library of IL-17RAmutants incorporating diversity
based on evolutionary information. The IL-17RA library was
screened using yeast surface display (YSD), followed by ELISA
screening of single mutants expressed in mammalian cells.
Two improved IL-17RA variants exhibited higher affinity, thermo-
stability, and inhibition of IL-17A-induced IL-6 and Gro-a secre-
tion both in a cell line and in mice, relative to the wild-type
(WT) receptor. Further analysis of one of these mutants in the
psoriasis mouse model showed a significant inhibition of psori-
asis plaque formation that is similar to the effect of dexametha-
sone, highlighting the potential of utilizing engineered soluble
IL-17RA as drug candidate for autoimmune diseases.
RESULTS
Generation of IL-17RA-ECD Gene Libraries
The IL-17RA receptor is a type I transmembrane protein contain-
ing an N-terminal signal peptide, followed by a 291-amino acid
(aa) long ECD, a 21-aa long transmembrane domain, and
a 521-aa long cytoplasmic tail (Yao et al., 1997). We cloned the
full length ECD of the receptor, consisting of 291 residues, as a
first step in the generation of IL-17RA mutant library. Next, we
used multiple sequence alignment of IL-17RA ECD to generate
a focused back-to-consensus IL-17RA library (Figure S2) (Berger
et al., 2011; Lehmann and Wyss, 2001). In recent years, several
approaches have been developed to generate small and func-
tionally rich gene libraries based on the structure, function and
evolution of the target protein (Lutz, 2010). One of these
approaches is by targeted mutagenesis of residues that deviate
from the consensus sequence of the gene family to generate
a back-to-consensus library (Amar et al., 2012; Berger et al.,
2011; Lehmann and Wyss, 2001). This library approach was
shown to enhance the stability and activity of the target protein
(Bershtein et al., 2008; Bloom et al., 2006).To identify target resi-
dues that deviate from the family consensus in the IL-17RA ECD,
six mammalian IL-17RA sequences were aligned. We identified
16 different positions that deviate from the IL-17RA family
consensus (Table S1). To generate a IL-17RA gene library con-
taining back-to-consensus mutations, we adapted a recently
developed methodology termed ISOR (incorporation of syn-
thetic nucleotide via gene reassembly) (Herman and Tawfik,
2007) for partial mutagenesis of the targeted positions. This
methodology is an adaptation of gene shuffling and allows simul-
taneous diversification of specific residues by spiking with
synthetic oligonucleotides containing the desired mutations
during the gene assembly process (Stemmer, 1994) (Figure S2B).
Following library generation, sequencing of 14 random IL-17RA
library variants indicated an insertion of two to seven back-to-
consensusmutations per gene with an average of four mutations
per gene. Each library variant carried a random and different
subset of mutated residues (data not shown). The complexityChemistry & Biology 20, 202of the library, given an average insertion of four back-to-
consensus mutations per gene, is 20,000 mutants.
Enrichment of the IL-17RA Library Using Yeast Surface
Display
YSD is a powerful method for engineering proteins with
increased affinity, specificity, and stability (Chao et al., 2006).
The YSD approach provides several advantages over other
methods for high-throughput screening of large mutant libraries.
This approach enables quantitative screening of large libraries
through the use of fluorescence-activated cell sorting, allowing
the real-time analysis of the library characteristics and fine-
tuning of the selection threshold (Chao et al., 2006). We have
utilized the YSD approach to display the IL-17RA on the yeast
cell surface and to examine its binding to IL-17A (Figure 1). The
display level of IL-17RAwasmonitored using fluorescein isothio-
cyanate (FITC)-labeled antibodies against the myc tag intro-
duced at the C terminus of the protein. Binding to IL-17A was
monitored using biotinylated a-IL-17A antibodies followed by
incubation with streptavidin conjugated to allophycocyanin
(APC). We found that the WT IL-17RA is displayed on the yeast
cell surface at low levels, relative to the proliferating cell nuclear
antigen (PCNA) protein from Saccharomyces cerevisiae ex-
pressed under identical conditions (Fridman et al., 2010) (Fig-
ure 1B). To enrich the naive library for mutants with enhanced
display levels and affinity to IL-17A, yeast cells displaying the
IL-17RA library were incubated with IL-17A and more than 5 3
106 cells were analyzed and sorted by fluorescence-activated
cell sorting (FACS) based on a fluorescence expression and
binding signal. Two iterative rounds of enrichment were per-
formed leading to a continuous increase in the mean fluores-
cence of the population (Figures 1C and 1D). In parallel, we
have generated and examined random mutagenesis library of
IL-17R containing two to six random mutations using YSD fol-
lowed by FACS sorting. We found that the random mutagenesis
IL-17R library did not exhibit significant enrichment for active
clones following two rounds of FACS sorting, highlighting the
lower frequency of active clones relative to the back-to-
consensus library (Figure S3).
Screening of the Enriched IL-17RA Library Using ELISA
To identify single IL-17RA mutants with enhanced expression
and/or binding affinity for IL-17A, the FACS-enriched library
was subcloned into a bacterial plasmid, overexpressed in Es-
cherichia coli, and screened by ELISA. To facilitate the screening
of a large number of E. coli extracts containing IL-17RAmutants,
we developed a fast and sensitive ELISA for the detection of IL-
17RA-IL-17A interaction (Figure S4). The assay is based on im-
mobilizing IL-17A on multiwell plates and detecting IL-17RA
binding using specific antibodies. To examine the dynamic range
for detection of the IL-17RA-IL-17A interaction, we varied the
concentrations of the IL-17RA applied to the plate and found
that the assay is highly sensitive and can detect a large range
of IL-17RA concentrations (Figure S4B). Using this assay, the
crude cell lysates of 90 IL-17RA mutants from the FACS-en-
riched library were screened for binding to IL-17A. The naive
library was also directly subcloned into a bacterial plasmid, over-
expressed in E. coli, and screened by ELISA. Comparison of
the two screening experiments clearly indicates that library–211, February 21, 2013 ª2013 Elsevier Ltd All rights reserved 203
Figure 1. YSD of the Extracellular Domain of IL-17RA
(A) IL-17RA is displayed as an Aga2 fusion protein on the surface of yeast. Expression is detected using fluorescent antibodies binding to the c-myc tag. Binding of
IL-17RA to IL-17A is detected using biotinylated a-IL-17A antibodies and then fluorescently-labeled streptavidin.
(B) FACS histogram analysis of cells displayingWT IL-17RA (red), the PCNA that was used as a positive control (green), and yeast cells containing no plasmid that
was used as a negative control (black).
(C and D) Enrichment of the IL-17RA back-to-consensus library using YSD for higher display level and binding to IL-17A. FACS histogram analysis of cells
displaying the naive library (black) and the library following one round (blue) or two rounds (orange) of enrichment. Expression of IL-17RA mutants was examined
following incubation with FITC-conjugated antibodies directed against the c-myc epitope (C). Binding to IL-17A was measured following incubation with IL-17A,
biotinylated antibodies, and APC-labeled streptavidin (D).
See also Figures S2 and S3 and Table S1.
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positive clones by a factor of four, relative to the naive library
screened without pre-enrichment steps (Table S2). Overall, the
first round of evolution using YSD and E. coli expression systems
yielded 22 mutants with increased binding signal relative to the
WT IL-17RA (Table S3).
Mammalian Cell Expression andCharacterization of Ten
Selected IL-17RA Mutants
Recombinant proteins expressed and purified from E. coli lack
posttranslational modifications that would occur using mamma-
lian expression systems (Durocher et al., 2002). It was previously
shown that the extracellular domain of many receptors is highly
glycosylated and that such glycosylation can significantly204 Chemistry & Biology 20, 202–211, February 21, 2013 ª2013 Elsecontribute to receptor conformation and binding to the target
ligand (Tootle and Rebay, 2005). Indeed, we found that the
mobility of the ECD domain of IL-17RA on SDS-PAGE reflects
that of a protein with a much higher molecular weight than pre-
dicted based on the amino acid sequence (Figure S5). We thus
decided to express and purify ten of the IL-17RA mutants from
the back-to-consensus library in mammalian cells (V1–V10,
Table S3) based on their binding level examined by ELISA
and the distribution of the back-to-consensus mutations. For
mammalian expression, V1-V10 mutants were subcloned into
mammalian vector containing the IL-17A natural leader peptide
and fused with human IgG1 Fc. The proteins were expressed
in HEK293 cells and purified using protein A affinity chromatog-
raphy (see Experimental Procedures for details). The resultingvier Ltd All rights reserved
Table 1. Kinetic Rate Constants of IL-17A Cytokine Binding to IL-
17RA Variants, as Determined by SPR
Immobilized
Ligand ka (1/Ms) kd (1/s) Kd (M)
Fold
Increase
in Affinity
WT IL-17RA 1.54 3 105 4.04 3 104 2.62 3 109 ± 0.04 –
V3 1.70 3 105 7.51 3 105 4.43 3 1010 ± 0.2 6
V10 1.84 3 105 1.15 3 104 6.243 1010 ± 0.15 4.2
Figure 2. Thermal Inactivation of WT IL-17RA, V3, and V10 Mutants
The IL-17RA variants were incubated at different temperatures for 30 min, and
residual IL-17RA binding to IL-17A was monitored at room temperature using
ELISA. The results were normalized relative to the variant binding following
incubation at 50C. The heat inactivation temperatures derived from the fits are
57.1 ± 0.6, 63.8 ± 1.2, and 63.9 ± 0.5 for the WT (triangle), V3 (filled circle), and
V10 (empty circle), respectively. Each data point is the average of two inde-
pendent experiments, see details in the Experimental Procedures section.
See also Figures S5, S6, and S8 and Table S4.
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tained low amounts of lipopolysaccharide (LPS) suitable for
testing in human cell line (Table S4). Next, we characterized
the ability of the different variants, expressed and purified from
mammalian cells, to bind IL-17A using ELISA. We found that
two variants, V3 and V10, showed higher binding, relative to
WT IL-17RA expressed and purified under identical conditions
(Figure S6). To quantitatively characterize the IL-17A binding
affinity to V3, V10, and WT IL-17RA, we measured the associa-
tion and dissociation rate constants between these proteins
using surface plasmon resonance (Table 1). We found that the
affinity of the WT IL-17RA to IL-17A is 2.6 nM, a value that is in
excellent agreement with the previously reported IL-17A binding
affinity (Ely et al., 2009; Wright et al., 2008). Interestingly, we
found that V3 and V10 exhibit 6- and 4-fold increased IL-17A
binding affinity, respectively, relative to WT IL-17RA (Table 1).
Stability of the IL-17RA Mutants
To examine whether the back-to-consensus mutations in V3 and
V10, expressed in mammalian cells, affect the thermostability of
the proteins, we examined the residual activity of these mutants
following incubation at high temperatures, relative to the WT
protein. We thus incubated V3, V10, and WT IL-17RA for
30 min at different temperatures, ranging from 37C to 70C,
and characterized their residual activity using ELISA. We found
that incubation of the proteins at temperatures between 37C
and 50Chad no effect on the IL-17RA binding activity. However,
we observed a gradual decrease in the WT binding activity at
temperatures higher than 50C, with almost complete loss of
activity at60C (Figure 2). In contrast, both V3 and V10 variants
were highly active following incubation at 60C and exhibit an
increase in temperature of inactivation of 7C (Figure 2). To
further study the stability of the protein in the human serum,
we incubated IL-17RA WT, V3, and V10 with human serum for
5 hr at two different temperatures, 37C and 40C, and assessed
their residual activity using the IL-17A ELISA binding assay. As
a control, we incubated the proteins in PBS under identical
conditions. We observed a decrease of up to 33% in activity
for the WT IL-17RA following incubation at 40C, relative to
PBS (Figure S7). In agreement with the thermostability analysis
of the V3 and V10 (Figure 2), we observed lower levels of inacti-
vation of these proteins following serum incubation, relative to
the IL-17RA. These results show that V3 and V10 exhibit higher
stability than the WT protein in the human serum.
Examining theContribution of theDifferentMutations to
IL-17A Activity and Thermostability
To examine the contribution of the back-to-consensus muta-
tions identified in V3 and V10 to the activity and thermostabilityChemistry & Biology 20, 202of the proteins, we generated and examined a series of site-
directed mutants. We mutated the majority of the mutations
found in V3 and V10 individually back to the WT residue (Table
2). For example to assess the contribution of the K109R
mutation in V3, we generated a V3 variant in which residue
R109 is mutated to K, where K is the WT residue at this posi-
tion. These mutants were expressed in mammalian cells to
maintain posttranslational modifications and examined for
binding to IL-17A using ELISA. In addition, we examined the
thermostability of the active mutants following 30 min of
incubation at elevated temperatures and characterized their
residual activity using ELISA (as described previously). Detailed
analysis of single mutants of the V3 indicated that two back-
to-consensus mutations, D123G and H156D, are completely
essential for IL17-RA binding to IL-17A (Table 2). Interestingly,
we found that R109K mutation results in an 50% decrease
in binding to IL-17A but significant decrease in thermostability.
Similar analysis of mutations in V10 confirmed the impor-
tance of D123G and R109K for IL-17A binding and thermosta-
bility, respectively. The V10 analysis also revealed that F60V
mutation is crucial for IL-17A binding. Our mutational analysis
shows that most of the back-to-consensus mutations are
essential to IL-17RA binding and indicates that these mutations
cooperatively contribute to IL-17RA activity. However, this
analysis suggests that it is possible to reduce the number of
mutations in V3 by back mutation of L10P, G244W, and
A268V, enabling a decrease in the risk of immunogenicity
following administration. Mapping the mutations present in
the V3 and V10 mutants on the recently solved crystal structure
of WT IL-17RA ECD (Ely et al., 2009) revealed that most of the
mutations are scattered on the outer surface of the protein
(Figure S8).–211, February 21, 2013 ª2013 Elsevier Ltd All rights reserved 205
Table 2. Mutational Analysis of V3 and V10 IL-17RA Variants
IL-17RA
Varianta Mutationsb
IL-17Ac Binding
Relative to the
Parental Protein (%) Ti (C)d
V3 L10P, R109K, D123G,
H156D, G244W, A268V
100 62
V3 P10L R109K, D123G, H156D,
G244W, A268V
85 62
V3 K109R L10P, D123G, H156D,
G244W, A268V
45 58
V3 G123D L10P, R109K, H156D,
G244W, A268V
<5 ND
V3 D156H L10P, R109K, D123G,
G244W, A268V
<5 ND
V3 W244G L10P, R109K, D123G,
H156D, A268V
65 62
V3 V268A L10P, R109K, D123G,
H156D, G244W
80 62
V10 L10P, F60V, R109K,
D123G, A157P
100 62
V10 V60F L10P, R109K, D123G,
A157P
10 ND
V10 K109R L10P, F60V, D123G,
A157P
80 58
V10 G123D L10P, F60V, R109K,
A157P
<5 ND
ND, Not determined.
aIL-17RA variants were expressed in mammalian cells. The back-to-WT
mutations in V3 and V10 are highlighted in bold.
bList of mutations in each variant following the mutagenesis of V3
or V10.
cBinding of the IL-17RA V3 and V10mutants wasmeasured by ELISA and
compared to the unmutated V3 or V10 variants, respectively.
dTemperature of inactivation determined by the residual binding level
following incubation at various temperatures (see Figure 2 for examples).
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Mutants
To examine the ability of the recombinant IL-17RA mutants, ex-
pressed in mammalian cells, to inhibit IL-17A binding to the
endogenous IL-17RA receptor in cells, we established a cell-
based assay to measure the level of IL-17A-induced cytokine
secretion. The assay is based on measuring Gro-a and IL-6
secretion following IL-17A addition to human fibroblast cells.
The addition of soluble IL-17RA together with IL-17A prevents
ligand binding to the endogenous IL-17RA receptor due to
competition, thus leading to reduced IL-6 and Gro-a secretion.
We found that addition of increasing concentrations of IL-17RA
to the fibroblast cells together with 10 ng/ml IL-17A is sufficient
to inhibit IL-17A-induced Gro-a and IL-6 secretion (Figure S9).
We found that the inhibition of Gro-a secretion was consistent
with the inhibition of IL-6 secretion, indicating a decreased level
of IL-17A binding to the endogenous receptor (Figure S6). Next,
we tested the ability of the V3 and V10 mutants to inhibit IL-17A-
induced Gro-a secretion relative to theWT protein. Bothmutants
were able to inhibit Gro-a secretion in human fibroblasts at lower
concentrations than did the WT protein (Figure 3). We found that
the presence of V3 and V10 at concentrations of 0.25 and206 Chemistry & Biology 20, 202–211, February 21, 2013 ª2013 Else0.1 mg/ml, respectively, leads to at least 90% inhibition of IL-
17A induced Gro-a secretion (Figure 3).
To further examine the in vivo inhibitory activity of IL-17RA on
IL-17A-induced Gro-a secretion in mice, we first calibrated the
amount of IL-17A injection and the duration of time that is
needed to obtain optimal levels of Gro-a secretion in mice
(data not shown). We found an increase of 18 fold in Gro-a
levels in blood samples of mice collected 2 hr after IL-17A injec-
tion (1.5 mg/kg; Figure 4). To validate that the IL-17A indeed
leads to elevated levels of Gro-a secretion, we injected IL-17A
following pre-incubation with antibody against IL-17A and
observed a decrease of 35% in Gro-a secretion levels (Fig-
ure 4). The antibody against IL-17A was used at a relatively low
concentration and served as a positive control for verifying the
IL-17A induced Gro-a secretion in vivo. Next, IL-17A was in-
jected into mice with or without pre-incubation with WT IL-
17RA, or the V3 or V10 mutants. We found that the injection of
IL-17A following pre-incubation with WT IL-17RA led to an
inhibition of 65% in Gro-a secretion (Figure 4). Interestingly,
pre-incubation of the IL-17A with the V3 or V10 mutant led to
inhibition of 70% and 82% in Gro-a secretion, respectively,
that is higher than the inhibitory effect observed for the WT
protein (Figure 4). This result is in excellent correlation with the
increased IL-17A binding affinity of these mutants, relative to
the WT protein (Table 1).
In Vivo Analysis of IL-17RA V3 Mutant in the Psoriasis
Mouse Model
To assess the therapeutic potential of V3 variant in the recovery
of psoriasis lesions, we examined the therapeutic effect of V3,
expressed in mammalian cells, in a psoriasis mouse model. To
establish such a model, skin samples from psoriasis patients
were transplanted into SCID mice and 28 days following skin
transplant, IL-17RA V3 was administered via subcutaneous
injection twice a week for 4 weeks. We have examined different
concentrations of V3 including 3.5, 7, 14, and 28 mg/kg. After
56 days from the initial skin transplant, the mice were sacrificed
and the recovery of the psoriasis lesions was assessed histolog-
ically. The level of recovery was scored from 1 to 4, where 1 is the
psoriasis form, 2 is partial recovery, 3 is partial to complete
recovery, and 4 is complete recovery. As expected, we found
that there was psoriasis disease present in six of eight of the
mice treated with PBS (Figure 5; Table S5). Treatment with dexa-
methasone inhibited disease in six of eight mice, similar to histor-
ical data within this model (Nair and Nair, 1975). We found the
administration of 7 mg/kg of V3 led to inhibition of the disease
in six of eight mice and the effect was slightly higher than that
with dexamethasone, which was used as a positive control
(Figure 5; Table S5). We found an attenuated response at
lower or higher V3 concentrations, highlighting the optimality of
7 mg/kg for the treatment of psoriasis in the mouse model (Fig-
ure 5; Table S5).
DISCUSSION
In this work, we employed a directed evolution approach to
generate an improved soluble IL-17RA receptor with increased
IL-17A binding affinity, stability, and inhibition of IL-17A-induced
secretion of cytokines. The binding of IL-17 to its endogenousvier Ltd All rights reserved
Figure 3. The V3 and V10 Variants Are More
Potent in Inhibiting IL-17A-Induced Secre-
tion of Gro-a in Human Fibroblasts than Is
WT IL-17RA
Cells were incubated for 24 hr with 10 ng/ml hIL-
17A and different concentrations of soluble IL-
17RAWT andmutant receptors. The undiluted cell
supernatant was analyzed by ELISA for detection
of Gro-a levels. The values presented here were
calculated following subtraction of the basal Gro-a
secretion signal (OD450 = 0.2). The data represent
the average of three independent repeats of each
experiment and the error bars represent the
standard deviation from the average.
See also Figures S5, S6, S8, and S9 and Table S4.
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inflammatory conditions and autoimmune diseases (Gaffen,
2009). Thus, the direct inhibition of IL-17A binding using a
soluble receptor can lead to the prevention of inflammatory
conditions and may provide beneficial therapeutic effects. Other
approaches for direct blocking of IL-17A interaction include
the use of antibodies against the IL-17A or IL-17RA. Currently,
humanized antibodies for these proteins are in different stages
of clinical trial for several conditions, including RA, Crohn dis-
eases, and psoriasis (Kopf et al., 2010). In contrast, to the best
of our knowledge, no soluble IL-17 receptor is in clinical trial
despite the high potential of this therapeutic approach for block-
ing IL-17-induced inflammation. Other indirect approaches that
target IL-17A-induced signaling affect upstream or downstream
mediators of IL-17A signaling, such as MAP kinases (Laan et al.,
2001; Prause et al., 2003).
The use of soluble receptors for blocking ligand-receptor inter-
actions may have unique therapeutic effects in different indi-
vidual and disease states (Gershoni, 2008; Huang, 2009). This
approach allows neutralization of the target ligand through native
ligand-receptor binding mode in contrast to antibodies that can
bind the target ligand through different interaction regions. The
first successful example of using a soluble receptor as a thera-
peutic drug is the TNF-a soluble receptor (Etanercept), which
is composed of the soluble ECD of the TNF-a receptor II fused
to the Fc domain of the IgG1 (Mohler et al., 1993; Peppel et al.,
1991). This soluble receptor neutralizes both the membrane-
bound and the soluble forms of TNF-a and, therefore reduces
the concentration of serum inflammatory cytokines (Mohler
et al., 1993; Peppel et al., 1991). This approach mainly utilizes
the WT extracellular domain to trap the target ligand. The ability
to engineer soluble receptors for higher ligand binding affinity
and stability can increase the potency and applicability of the
latter as therapeutic drugs. Indeed, our results indicate that the
engineered IL-17RA V3 and V10 mutants exhibit higher IL-17A
binding affinity in vitro and increased levels of inhibition of IL-
17A-induced Gro-a secretion both in a cell line and in vivo using
a mouse model (Figures 3 and 4). The immediate challenges that
still remain until the protein becomes a drug are the validation
that mutations that lead to improved ligand binding affinity and
stability do not lead to immunogenicity, examination of the phar-Chemistry & Biology 20, 202macokinetics of the engineered receptor, and further preclinical
development. Analysis of potential immunogenicity of the WT
IL-17RA, V3, or V10 proteins was performed by searching
the protein sequences for known human immune epitopes
using the epitope database (http://www.immuneepitope.org/).
No human immune epitopes were identified within the IL-
17RA,V3, and V10 sequences reducing the risk for immunoge-
nicity of these proteins in humans.
One efficient way for increasing protein function using a
directed evolution methodology involves inserting back-to-
consensus mutations into the protein sequence for the genera-
tion of small and effective gene libraries. Such an approach
implements evolutionary information based on sequence align-
ment and is a modification of the conventional family DNA shuf-
fling process for the generation of gene libraries (Herman and
Tawfik, 2007; Bershtein et al., 2008; Bloom et al., 2006). Indeed,
focused IL-17RA library containing different combinations of
back-to-consensus mutations contained relatively high per-
centage of variants exhibiting increased binding following
expression in E. coli (Table S2). We found that pre-enrichment
using YSD further reduced the need for extensive screening
and increased the number of positive clones for downstream
analysis (Table S2). Previously, consensus and ancestral muta-
tions were systematically studied and found to significantly
increase the activity and thermostability of different target
proteins (Tokuriki and Tawfik, 2009). Mapping of the back-to-
consensus mutations identified in V3 and V10 on the IL-17RA
crystal structure (Ely et al., 2009) reveals that most of these
mutations are located on the surface of the receptor (Figure S8).
These mutations can probably lead to increased stability and IL-
17A binding affinity by minor indirect effects on the conformation
and solubility of the IL-17RA mutants. Detailed analysis by site-
directed mutagenesis of the majority of these mutations back
to the WT residues (Table 2) indicates the contribution of indi-
vidual residues to the binding affinity and stability of the V3
and V10 variants. We found that the majority of the back-to-
consensus mutations are essential for the activity or thermosta-
bility of the variants, indicating a cooperative mode of action of
these mutations.
In vivo analysis of the improved IL-17RA mutants indicated
that the increase in IL-17A affinity and stability of these mutants–211, February 21, 2013 ª2013 Elsevier Ltd All rights reserved 207
Figure 4. The V3 and V10 Variants Inhibit IL-
17A-Induced Secretion of Gro-a in Mice
More Efficiently than Does WT IL-17RA
Injection of IL-17A (1.5 mg/kg) into groups of
mice (n = 5 in each group) leads to significant
increases in Gro-a levels. Pre-incubation of IL-17A
with antibody against IL-17A (2 mg/kg), WT IL-
17RA, V3, or V10 leads to inhibition of Gro-a
secretion. The antibody against IL-17A was used
as a positive control for IL-17A-induced Gro-a
secretion in vivo. We found that the inhibition of
IL-17A-induced Gro-a secretion is significantly
higher with the V3 or V10 than the inhibition ob-
tained with WT. All IL-17RA variants were injected
at a concentration of 14 mg/kg and Gro-a levels
were analyzed in blood samples collected 2 hr
after injection (see Experimental Procedures for
detailed description). The data represent the
average of five independent measurements (five
mice in each group) and the error bars represent
the standard deviation from the average.
See also Figures S7 and S8.
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IL-17A-induced cytokine secretion in the mouse model. These
results highlight the potential of directed evolution in generating
engineered proteins with superior properties in vivo relative to
the WT protein. In addition, we found the IL-17RA V3 mutant
can effectively promote the recovery of psoriasis lesions in the
mousemodel. This result is in agreement with the recent success
of antibodies against IL-17A or IL-17 receptor in phase 2 clinical
trials for the treatment of psoriasis (Leonardi et al., 2012; Papp
et al., 2012). The use of a soluble receptor provides a means
for IL-17A inhibition that can be complementary to antibodies
as a drug candidate for psoriasis. Such an approach provides
the advantage of targeting IL-17A at its receptor binding site
allowing efficient competition with the endogenous IL-17RA
cell surface receptor. In addition, this soluble receptor can
be examined in other autoimmune diseases, including Crohn
disease and RA.
SIGNIFICANCE
IL-17 is a proinflammatory cytokine involved in the progres-
sion of several common autoimmune diseases, such as
rheumatoid arthritis, psoriasis, and inflammatory bowel
disease. Inhibition of IL-17A proinflammatory activity is
achieved mainly by antibodies targeting the IL-17A itself or
its endogenous receptor. Here, we utilized directed evolu-
tion to generate soluble IL-17RA with improved properties
for the inhibition of IL-17A binding to its endogenous
cell surface receptor. Our results show that engineered IL-
17RA exhibiting increased IL-17A binding affinity and
stability can inhibit IL-17A-induced cytokine secretion in
cell line and in vivo, demonstrating the power of protein
engineering for generating proteins with improved in vitro
and in vivo activities. Moreover, the ability of the engineered
receptor to promote the recovery of psoriasis plaque inmice
highlights its potential as a drug candidate for this common
autoimmune disease. Targeting IL-17A by the engineered IL-
17RA can serve as a complementary approach for existing
approaches utilizing antibodies and may efficiently target208 Chemistry & Biology 20, 202–211, February 21, 2013 ª2013 Elsethe precise regions in IL-17A involved in the interaction
with its endogenous cell surface receptor. We think that
directed evolution can serve as a general approach for the
engineering of soluble receptors for increased stability and
activity, for the study of ligand-induced cell responses, and
as a first step for the generation of a newclass of therapeutic
agents for a wide range of diseases.
EXPERIMENTAL PROCEDURES
Plasmids
The human IL-17RA extracellular domain was amplified from EST cDNA clone
of human IL-17RA purchased from Open Biosystems. For E. coli expression,
the ECD of the gene was cloned into the pET32 plasmid (Novagen). Cloning
was performed using NcoI and NotI sites to yield a thioredoxin (Trx)-6x Histi-
dine-tagged version of the protein. The E. coli Clooni strain (Lucigen) was
used for cloning and plasmid extraction. For YSD, the variants were cloned
into the pCTCON plasmid using the NheI and BamHI sites (Chao et al.,
2006). For expression in mammalian cells, the pFUSE (Invivogen), pFW02
(CrownBio) and pYD11 (CrownBio) vectors were used to yield IL-17RA-ECD
variant fused with human IgG1 Fc to increase the serum half-life of IL-17RA
(Huang, 2009). Primers used for the cloning and library construction are listed
in Table S6.
Yeast Surface Display
IL-17RA variants were displayed on the yeast cell surface of EBY100 strain
cells (see (Chao et al., 2006) for genotype) and analyzed by flow cytometry,
essentially as described (Bloom et al., 2005). Briefly, EBY100 cells transformed
with plasmid pCTCON containing the desired clone were grown in SDCAA
media (20 g sucrose, 6.7 g yeast nitrogen base, 5 g casamino acids, 5.4 g
Na2HPO4, and 8.56 g NaH2PO4 3 H2O) at 30
C to logarithmic phase. Then,
23 106 of cells were washed, resuspended in SGCAA induction media (similar
to SDCAA but containing galactose instead of sucrose), and grown at 37C
with shaking for an additional 18 hr. Induced cells (1 3 106) were collected
by centrifugation, washed with PBSF (PBS + 1 g/L BSA) and incubated for
1 hr at 25C with 0.2 mM hIL-17A (R&D Systems). The cells were then washed
and incubated for 1 hr at 25C with mouse a-myc antibodies (Santa Cruz
Biotechnology, 1 ml/50 ml PBSF) and goat biotinylated a-hIL-17A (R&D
Systems, 0.25 ml/50 ml PBSF). Subsequently, cells were washed again and
incubated with FITC-conjugated a-mouse IgG (Sigma, 1 ml/50 ml PBSF) and al-
lophycocyanin- conjugated streptavidin (Jackson Immunoresearch, 1 ml/50 ml
PBSF) for an additional hour on ice, with frequent mixing. The labeled cells
were washed, resuspended with PBSF, and analyzed by flow cytometry
(FACS Calibur, BD).vier Ltd All rights reserved
Figure 5. TheRecovery of Psoriasis Lesions
following Administration of V3 IL-17R
Variant at Different Concentrations
A dose response for V3 activity is observed
between 3.5 and 7 mg/kg; attenuated activity at
higher doses was observed. Doses were admin-
istered via subcutaneous injection twice a week
for 4 weeks in the psoriasis model at con-
centrations of 3.5, 7, 14, and 28 mg/kg. The data
represent the average of eight independent mea-
surements (eight mice in each group) and the error
bars represent the standard deviation from the
average.
See also Figure S7 and Table S5.
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For the generation of IL-17RA back-to-consensus library, the human IL-17RA
gene was amplified by PCR, and 10 mg were digested with DNaseI to yield
50–125 bp fragments, as previously described (Stemmer, 1994). The frag-
ments were reassembled, as in DNA shuffling (Aharoni et al., 2004), in the
presence of a mixture of 18 short oligonucleotides (4–6 nM each, Table S5),
resulting in a library containing two to seven mutations in each gene with an
average number of four mutations (Aharoni et al., 2004; Stemmer, 1994). The
estimated complexity of the library is 20,000 mutants based on the following
equation: N!/(N-K)! 3 K, where N is the total number of positions (18) and K is
the average number of mutations inserted into the gene (four). The reaction
mixture was further amplified by nested PCR, as described (Chao et al.,
2006). The assembled libraries were ligated into the pET32 vector for E. coli
expression and into the pCTCON vector for YSD. Error-prone libraries were
generated with mutagenic dNTP analogs, 8-oxodG and dPTP (Zaccolo
et al., 1996), and two to six mutations per gene were obtained. The library
was then ligated into the pCTCON vector for YSD.
Library Selection Using Yeast Surface Display
The naive library was induced and labeled with c-myc and IL-17A, as
described above. EBY100 cells (1 3 107) displaying the IL-17RA library were
labeled, analyzed, and sorted using a FACS (Vantage, BD). Two iterative
rounds of enrichment were performed. In each round, multiple positive events
(3–5 3 104), corresponding to cells found within the top 1%–2% of the green
and red fluorescence intensity area, were collected into growth media and
plated on agar for a new round of enrichment. For initial sorting of the naive
library, a sorting gate of the top 5% of fluorescent cells was used. Selection
rounds were continued until no further enrichment was obtained.
Cloning and Bacterial Expression of IL-17RA-ECD Variants
A pool of plasmids from the last round of FACS enrichment was PCR-ampli-
fied, cloned into plasmid pET32 and transformed into the E. coli BL21 (DE3)
strain (Novagen). In parallel, the naive library was directly cloned into pET32
plasmid and transformed into the E. coliBL21. Following transformation, single
colonies were inoculated into 10 ml LB media containing 100 mg/ml ampicillin,
grown to OD600 of 0.6, and induced with 1 mM of IPTG (Calbiochem) overnight
at 30C. The cells were then harvested; lysed in PBS supplemented with 0.2%
Triton, 200 mg/ml lysozyme (Calbiochem), and 10 mM b-mercaptoethanol;
centrifuged; and the cleared supernatant was collected and analyzed with
ELISA (see below). We screened 180 mutants from the naive library and 90
mutants from the FACS-enriched library to identify clones with improved
activity relative to the WT protein.
Protein Expression in Mammalian Cells
For large-scale purification of IL-17RA variants, HEK293F cells were tran-
siently transformed with 1 mg/ml of DNA at a DNA/PEI ratio of 1:3 or 1:4, and
harvested after 6–7 days. The recombinant proteins were purified on a HiTrap
Protein A HP column, with 20mM sodium phosphate, pH 7.0, as binding bufferChemistry & Biology 20, 202and 100 mM sodium citrate, pH 3.0, as elution buffer. The proteins were then
analyzed by silver stain and western blot using specific antibodies against the
Fc, following SDS-PAGE. Purified proteins were stored at 80C in 50 mM
Tris, 200 mM NaCl, pH 7.5, until further analysis.
ELISA Assay for IL-17A Binding
ELISA plates (Griener Microlon 96W) were incubated with 100 ml of 0.5 mg/ml
goat a-hIL-17A antibodies (R&D Systems) for 1 hr, washed with PBS supple-
mented with 0.05% Tween-80 (PBST), and 100 ml of 0.35 mg/ml IL-17A (R&D
Systems or ProSpec Tany TechnoGene) were added to the plate for an addi-
tional hour. The plates were then washed with PBST and blocked by incuba-
tion with 100 ml of PBS supplemented with 3% skim milk for 1 hr. Following
blocking, the plates were washed and incubated with 100 ml of the cleared
lysate, cell media or purified protein, and shaken for 1 hr. IL-17RA (R&D
Systems) was added at a concentration of 6.25 mg/ml as a positive control,
and PBS supplemented with 1% BSA served as a negative control. Plates
were then washed with PBST, incubated with 100 ml of 0.05 mg/ml goat
a-hIL-17RA antibodies (R&D Systems), followed by incubation with secondary
peroxidase-conjugated streptavidin (Jackson, 1:10000 dilution). Finally, 100 ml
of horseradish peroxidase (HRP) chromogenic 3,30,5,50-tetramethylbenzidine
(TMB) substrate solution (Dako) were added. The reaction was stopped by
the addition of 1 M sulfuric acid and recorded at 450 nm using a Tecan Infinite
M200 plate reader.
ELISA Assay for the Detection of IL-17RA Expression in E. coli
ELISA plates (Griener Microlon 96W) were coated with 100 ml of 0.2 mg/ml
streptavidin (Pierce) and 100 ml of 0.05 mg/ml goat a-hIL-17RA antibodies
(R&D Systems). The plates were then blocked by incubation with PBS supple-
mented with 3% skim milk for 1 hr. Next, 100 ml of the cleared lysates were
added to each well and the plates were incubated with shaking for 1 hr at
room temperature. The plates were washed with PBST and incubated with
100 ml of mouse a-6xHis-tag antibodies (Santa Cruz Biotechnology, 1:2000
dilution), washedwith PBST and further incubated with secondary HRP-conju-
gated goat a-mouse antibodies (Jackson, 1:5000 dilution) for 1 hr. Finally, the
HRP chromogenic TMB substrate solution (Dako) was added and the reaction
was stopped by the addition of 100 ml of 1 M sulfuric acid and recorded at
450 nm using a Tecan Infinite M200 plate reader.
Protein Thermostability
For protein thermostability tests, the purified proteins and commercially
available IL-17RA were diluted in PBS with 1% BSA to a final concentration
of 5 mg/ml. The variants were then incubated for 30 min at different tempera-
tures (ranging from 37C to 70C). The reaction was terminated by transferring
the proteins to liquid nitrogen; the proteins were kept at80C and then tested
for their IL-17A binding activity with ELISA at room temperature. The residual
binding signal was fitted to logistic equation using Sigma plot software. Protein
stability of the different variants was also studied following incubation with
human serum (Sigma), and compared to that in PBS with 1% BSA. The–211, February 21, 2013 ª2013 Elsevier Ltd All rights reserved 209
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bated at 37Cand 40C for 5 hr, and then tested for their IL-17A binding activity
with ELISA.
Affinity Measurements Using Surface Plasmon Resonance
The affinity of IL-17A binding to IL-17RA variants was determined by surface
plasmon resonance (SPR) measurements on a ProteOn XPR36 (Bio-Rad)
instrument. All samples were in HBST buffer (10 mM HEPES with 0.15 M
NaCl, 3.4 mM EDTA, and 0.005% Tween-20, pH 7.2). A GLC Chip was air-
initialized and activated with EDC/S-NHS. Four micrograms from each of the
IL-17RA variants were diluted in acetate buffer, pH 5.5, and immobilized
onto the chip. After blocking available unbound sites on the chip with ethanol-
amine, the chip was washed with HBST buffer and rotated. IL-17A was run at
25 ml/min for 300 s at various concentrations (50, 25, 12.5, 6.25, and 3.125 nM),
followed by a 10-min dissociation step. Binding parameters were determined
with the Langmuir single binding site model, using the Bio-Rad’s proteOn
Manager software V2.1.2.05.
Fibroblast-Based Assay for the Inhibition of IL-17-Induced IL-6 and
Gro-a Secretion
The normal human skin fibroblast cell line, ATCC CRL2091, was used for the
assay. Cells were routinely maintained in completed MEM medium at 37C
with 5% CO2. Cell cultures for each experiment were allowed to reach 95%–
100% confluence, counted and checked for viability with 0.5% Trypan blue
solution (Biological Industries). Cells were then diluted to reach 105 cells/ml
density, and 100 ml of the cell suspension were added to each well of 96
well plates (Nunc) to obtain 104 cells/well. The plates were incubated at
37C in 5% CO2 for 24 hr until 95%–100% confluency, and then stimulated
for an additional 24 hr with 10 ng/ml IL-17A in the presence or absence of
different amounts of the IL-17RA variants. Dose response of the cell lines to
IL-17A was tested in each experiment by adding different amounts of IL-17A
(from 0 to 20 ng/ml). Cell culture supernatants were then collected and stored
at 20C until further analysis. Measurement of IL-6 and Gro-a in culture
supernatants were performed through the use of ELISA kits (R&D Systems
or PeproTech) according to manufacturer description.
In Vivo Experiments in Mice
Animal housing and care conditions were maintained according to Teva Phar-
maceuticals guidelines, and approved by Teva Pharmaceuticals committee on
animal use. Animal welfare was ensured during management, treatment and
sampling according to Israeli laws and regulations. At the end of studies
animals were sacrificed by CO2 asphyxiation. The number of the approved
application of the ethics committee for animal experimentation is IL-013-02-
2003. C57Bl female 8-week-old mice were put in quarantine for 3 weeks. At
the age of 11 weeks, the mice were divided into treatment groups (five mice
per group). The IL-17RA variants (14 mg/kg, CrownBio), antibody against
IL-17A (2 mg/kg, R&D), or PBS were pre-incubated for 20min at room temper-
ature with human IL-17 (1.5 mg/kg, PeproTech). Treatment involved two
subcutaneous injections at the flank area of the conjugate (400 ml/mouse).
Two hours post-injection, the mice were euthanized with isofluran and bled
from the orbital sinus. The bleeding was terminal and the mice were sacrificed
by cervical dislocation. The blood was centrifuged and sera were separated
and tested for the level of Gro-a using a Gro-a ELISA kit (R&D) according to
manufacturer’s instructions.
Examination of IL17RA in Psoriasis Mouse Model
For the psoriasis mouse model study, C.B-17/IcrHsd-scid-bg (SCID) mice
(Harlan Laboratories) at 2–3 months of age were used. Healthy human skin
pieces at a width of 0.4 mm and surface of 3 3 3 cm, were provided from
residual skin of plastic procedures from healthy nonpsoriatic donors (the
Plastic Department of the Rambam Medical Center, Haifa, Israel). Skin from
a single healthy donor was transplanted onto 48 mice divided into six groups
(each group consist of eight mice). For the isolation of peripheral blood mono-
nuclear cells (PBMC) from psoriatic patients, blood samples from eight
patients were taken at a volume of 20 ml/patient. PBMC were isolated from
these samples by ficoll gradient (Pharmacia) and cultured with 100 U of IL-2
per milliliter (Pepro Tech Inc, Rocky Hill, NJ) in medium composed of RPMI
1640, 10% human AB serum (Sigma, St. Louis, MO), 1% glutamine, and 1%210 Chemistry & Biology 20, 202–211, February 21, 2013 ª2013 Elseantibiotics (media components; Biological Industries, Kibbutz Beit Haemeck,
Israel). After 14 days, the cells were injected into the human skin explants on
the SCID mice. Natural killer (NK) cells from a single patient were suspended
in complete medium (RPMI 1640, 10 human AB serum, 1% glutamine, 1%
antibiotics, 100 U IL-2 per milliliter), at 106 cells per ml and injected into one
mouse in each group so that the treatment groups were homogenous (Gilhar
et al., 2002). Treatment groups were as follows: PBS-treated group was
a negative control (40 ml/mouse of PBS) from day 42 after skin transplant;
dexamethasone-treated group was a positive control (40 ml/mouse of Dexa,
50 mg/ml in PBS, 2 mg/mouse) from day 42 and administration of IL-17RA
V3 at concentrations of 3.5 mg/kg, 7 mg/kg, 14 mg/kg, and 28 mg/kg biweekly
from day 28. Four weeks after onset of treatment, the skin was harvested. At
this stage, skin grafts were blinded, given a code, and analyzed histologically
in a blinded fashion. Histologic assessment of the grafts was performed by
light microscopy and epidermal thickness was determined with an ocular
micrometer. The severity of psoriatic form is scored on a scale of 1–4 by
histology, where 1 is the psoriasis form, 2 is partial recovery, 3 is partial to
complete recovery, and 4 is complete recovery.
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